6 Decision-Makers. 6 Definitions of Value. 1 Deal.

Picture the conference room. You just delivered what you thought was a flawless presentation. The clinical data was compelling. The department head was nodding. The pilot results spoke for themselves.

But scan the faces around that table. The CMO is thinking about patient outcomes and readmission rates. The CNO is mentally calculating what this means for shift staffing and OR turnaround. The CFO has already opened a spreadsheet in their head, running total cost of ownership against a five-year depreciation schedule. The CIO is wondering how many integration tickets this will generate. Procurement is mentally red-lining your contract terms before you have even sent them. And the department head, the one who championed this internally, is quietly hoping this does not blow up in their face.

Six people. Six completely different filters. Each one can kill your deal with a single objection. Not one of them can approve it alone.

Welcome to selling into health systems in 2026.

The Silence After the Pilot

Research shows it takes 12-20 touchpoints over 12-24 months to close complex healthcare deals. But the number that should keep you up at night is not 12 or 20. It is the number of weeks between your successful pilot and the moment your champion stops returning calls.

You know the pattern. Everything was moving. The evaluation went well. Clinical staff loved the technology. Your champion sent you an email saying, "This is looking really good internally."

Then nothing. Three weeks of silence. You send a check-in email. Crickets. Six weeks pass. Finally, a brief reply: "We are still evaluating internally. I will circle back when there is an update."

What happened between "looking really good" and radio silence?

Your champion walked into a budget review meeting and tried to sell your solution to the CFO using clinical language. The CFO asked about total cost of ownership, payback period, and how this compares to the three other capital requests on the table. Your champion fumbled. The conversation moved on. Your deal did not die. It just lost its oxygen.

You did not lose on product. You did not lose on clinical evidence. You lost because nobody in that room could translate what your technology does into the language the CFO speaks.

The Skill That Separates Closers from Forecasters

The reps who consistently win these deals do not build six separate pitches. They build one integrated value story that shifts shape depending on who is listening. Think of it less like a presentation and more like a prism. Same light goes in. Different colors come out depending on the angle.

Here is what that looks like when it is done well.

Start with the clinical thread. A surgical guidance system reduces revision rates by 15%. For the CMO, that is fewer complications, better patient satisfaction scores, and stronger quality metrics that show up in their next board report. That conversation happens in the language of outcomes, evidence, and patient safety.

Pull the operational thread from the same data. Fewer revisions mean 20% fewer unplanned OR hours. For the CNO, that translates directly into predictable scheduling, reduced overtime, and staff who are not burning out covering emergency cases. You are not selling technology anymore. You are solving a staffing problem they have been fighting for two years.

Follow the money. Those recovered OR hours and reduced complications translate to roughly $2.4M in annual savings. For the CFO, you just turned a capital expense into a line item that pays for itself in fourteen months. Now your deal is not competing against the other three capital requests. It is funding them.

Address the technical reality. The system plugs into existing EMR workflows and meets HIPAA requirements without new infrastructure or a six-month IT project. For the CIO, you just removed the biggest objection they were going to raise in the next steering committee meeting.

Frame the commercial terms around confidence. Risk-sharing terms tied to clinical outcomes, with quarterly performance reviews and a clear exit ramp if results do not materialize. For procurement, you just made their job easier. They do not have to negotiate you down to feel like they did their job. The structure does it for them.

Arm your champion. Give the department head a two-page internal business case they can circulate without needing you in the room. Something they can forward to the CFO with a one-line email: "This is the summary I mentioned." For the department head, you just took the career risk out of recommending your solution.

Same technology. Same clinical data. Same pilot results. Six completely different conversations that all point to the same conclusion.

The Thread That Ties It Together

Clinical outcomes that drive operational efficiency that delivers financial returns. That is the connective tissue running through every one of those six conversations.

We call it the COF framework. Clinical. Operational. Financial. When you can trace an unbroken line from patient impact through workflow improvement to P&L impact, something shifts in the room. You stop being a vendor with a product to sell. You become a partner with a business case that makes everyone at the table look smart for saying yes.

Those 12-20 touchpoints over 12-24 months are not about persistence or staying top of mind. Each one is an opportunity to build value fluency with a different member of the buying committee. The CMO conversation in month three. The CFO conversation in month five. Procurement in month eight. Each touchpoint deposits another layer of translated value into the organization until the deal reaches a tipping point where approval becomes the path of least resistance.

Your Move This Week

Pull up your most important active opportunity. Write down every person who has influence over the decision, not just your main contact. Next to each name, write the single metric they are measured on. The number that shows up in their performance review.

Now connect those metrics into one continuous narrative. Can you draw a straight line from the clinical impact your technology delivers, through the operational improvement it creates, to the financial return it generates?

If you cannot, you just found the gap that is stalling your deal.

---

Dr. Gunter Wessels is the founder of LiquidSMARTS℠, a commercial engineering firm that helps high-tech healthcare suppliers improve pipeline velocity. He guarantees a 10% improvement in 90 days.

Have a deal stuck in committee? Reach out at gunter@liquidsmarts.com.